Atlas Trials

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Clinical trial NCT05742425 · RECRUITING

Trial details

NCT number
NCT05742425
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Start date
2023-03-01
Primary completion
2028-03-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.